Navigation Links
Natural secretion marks difference between mole and melanoma
Date:2/7/2008

hers concluded. "Inhibitors of BRAF have been developed but unfortunately have performed poorly in clinical trials.

We have shown that IGFBP7efficiently induces [cell death] in BRAFV600E-positive melanoma cell lines. The selective sensitivity of BRAFV600E-containing human cancer cell lines to IGFBP7, and the ability of IGFBP7 to suppress BRAFV600E-positive tumor growth in mice, suggest that IGFBP7 may have a role in treating malignancies harboring activating BRAF mutations."


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Scientists Develop Natural Protection for Stored Foods
2. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
3. SIV infection of natural hosts provides new insights into HIV disease complexity
4. Big Relief for Tiny Itch Mites Found in All Natural Spray Remedy
5. Natural aorta grafts have few side effects for infection-prone patients
6. Fitness Champion Natalie Waples to be Spokesperson for Natural Nutrition International Direct Marketing Campaign
7. New Herbal Water Creating Taste Sensation: Ayalas Herbal Water Has No Calories, No Preservatives and No Artificial Additives. Just All the Natural Benefits of Herbs!
8. Natural Protein Could Help Spot, Treat Liver Cancer
9. The Village Company Unveils Natural Bath and Body Solutions for Everyday Ailments
10. All-Natural Organic Yerba Mate and Organic Aloe Vera Exfoliating Soaps will Help Save Your Skin(TM)
11. New Nutraceutical That Stabilizes Blood Sugar Naturally is Introduced
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...be the fastest growing industry, but it has been s...t fast food chains are now entirely automated, mos...heir records on paper. , In a new position paper...d/policy/ehealth.pdf ) released today by the Ameri...est medical specialty organization says that colla...
(Date:5/16/2008)...ater: An AIDS Vaccine is Possible and,Still Urgent...ire/ -- Twenty-five years since the,discovery of H...dressing,the AIDS pandemic. Scientists have learne... any other pathogen, and have developed more drugs...ned. But this progress is not,enough. While it is ...
(Date:5/16/2008)...lly Residents to Eat Right, Move More and ... 16 /PRNewswire/ -- The last decade can be defined...ich seem to go in and out of,fashion like shoulder...n,slim. Two out of three Americans -- including 30...t or obese., A new campaign crossing the country,...
(Date:5/16/2008)...cells in cord blood more than 30-fold , ,...t uses natural killer (NK) immune system cells fro...leukemia cells in mice, researchers say. , The...n acute lymphocytic leukemia (ALL) and acute myelo...essive human leukemias, according to the study. ,...
Breaking Medicine News(10 mins):Health News:New E-health recommendations from ACP aim to improve health care quality, safety, and access 2Health News:World AIDS Vaccine Day 2008 2Health News:World AIDS Vaccine Day 2008 3Health News:World AIDS Vaccine Day 2008 4Health News:Message to Michigan Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Michigan Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:New Therapy Kills Human Leukemia Cells in Mice 2
...have provided some useful tips on prevention of sk...n// some of its risk factors and treatment. Accor... in development of skin cancer individuals who hav...eater disposition towards developing skin cancer b...
... friend of President Bush, a businessman-turned-...// on the president's health care proposals, he ha...s. He is promoting Bush's proposals to provide big... make hospitals and doctors prices available to co...
...st Anglia have found that gold nanoparticles are v...ese particles they say reveal the presence of pois... involve shipping samples back to a lab. This they...ions at crime scenes. Researchers led by Professo...
...t the virology lab of the St. Paul's Hospital, 19 ...locked freezer//. The vials were also labelled wit...ion of the persons the blood had been taken from. ...re puzzled over this bizarre theft. The samples we...
Other Medicine News:Health News:Prevent Skin Cancer with Lifestyle Changes 2Health News:Gold Nanoparticles Are Good Detectors Biological Toxins 2Health News:Strange Theft Of HIV Infected Blood Leaves Authorities Puzzled 2
(Date:5/16/2008)... NEW YORK, May 16 /- Pulmo ...ounced details of the methodology and,purpose of i...ar Imaging,technology for the diagnosis of Pulmona... will be carried out by the Pulmo BioTech subsidia...s: "Phase I Study of the Use,of PulmoBind for Mole...
(Date:5/16/2008)... BRIDGEWATER, N.J., May 16 /- Data fr...ower mean baseline hemoglobin (Hb) levels,and the ...e effect of,restrictions on reimbursement for eryt...atients on the nation,s blood supply, will be pres... (ASCO) Annual Meeting later this,month. The meeti...
(Date:5/16/2008)...ktar,s Technology Enables First-Ever PEGylation of...ted Therapeutic Activity, SAN CARLOS, Calif., May...(Nasdaq: NKTR ) announced initial results today f...ecan. The data shows significant,anti-tumor activi...tudy,also demonstrates that Nektar,s small molecul...
(Date:5/16/2008)...Single Molecule with Dual Mechanism May Offer Nove...ure Management, NEW ORLEANS, May 16 /PRNewswire-F...ator in the discovery and development of novel sma...33540, its first-in-class,Dual Acting Receptor Ant...lood pressure reductions in a Phase 2a study in pa...
Breaking Medicine Technology:Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8BioMarin to Present at the Rodman 26 Renshaw 9th Annual Healthcare Conference 1611 1Crystal Research Associates LLC Issues Executive Informational Overview 28R 29 28EIO 28R 29 29 on CEL SCI Corporation 709 1Crystal Research Associates LLC Issues Executive Informational Overview 28R 29 28EIO 28R 29 29 on CEL SCI Corporation 709 2Crystal Research Associates LLC Issues Executive Informational Overview 28R 29 28EIO 28R 29 29 on CEL SCI Corporation 709 3US government delays nanotechnology safety measures 1048 1US government delays nanotechnology safety measures 1048 2Medivation Announces Participation in Acumen BioFin Rodman 26 Renshaw 9th Annual Healthcare Conference 1605 1Medivation Announces Participation in Acumen BioFin Rodman 26 Renshaw 9th Annual Healthcare Conference 1605 2
...FirstCall/ --,Bionovo, Inc.,s lead drug candidate,...eatment of hot flashes associated with menopause.,...he company,s,double-blind, placebo- controlled, ra...50 or more moderate to severe hot flashes,per week...receiving,MF101 (5 grams/day), MF101 (10 grams/day...
...rstCall/ -- VION,PHARMACEUTICALS, INC. announced t... session at the 43rd Annual Meeting of The America...anticancer agent,Cloretazine(R) (VNP40101M) as a s...elapsed or refractory small cell lung cancer. , Th...1M) in two,separate subpopulations of small cell l...
Other Medicine Technology:Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 2Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 3Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 4Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 5Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 2Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 3Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 4
The Mitek CuffTack sutureless fixation device offers superior fixation strength for rotator cuff repairs. The implant firmly reattaches soft tissue to the bone with one step insertion. CuffTack is in
...imple to use system can be used for open or arthro... a sterile disposable inserter. The unique deploym... insertion of the anchor into bone. The Independe...lows for the two pre-threaded sutures to independe...
The Micro Anchor is the smallest, strongest anchor on the market allowing exceptional flexibility in placement into even the smallest bones. This anchor comes pre-loaded with 3-0 or 4-0 ETHIBOND EXCE
FASTIN RC is a threaded titanium anchor, specifically designed for rotator cuff procedures. The anchor features wide threads and a small core to optimize bone purchase, as well as independent suture
Medicine Products: